Liraglutide Treatment to Patients With Severe Renal Insufficiency
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is
new and fundamentally different from the classical treatments with oral antidiabetic agents
and insulin. The novel and original aspect of this investigator-initiated study is the focus
on treatment with an incretin-based agent (the GLP-1 analogue liraglutide) in T2D patients
with severely reduced kidney function. At present there is virtually no knowledge of the
physiology and clinical implications of the role of incretin hormones and incretin-based
therapy in this group of diabetic patients.The aim of the study is to establish an
evidence-based rationale for introducing a GLP-1 analogue to the limited armamentarium of
antidiabetic drugs for patients with type T2D and severe renal insufficiency. The overall
hypothesis is that patients with T2D and severe renal insufficiency will tolerate and benefit
from treatment with the GLP-1 analogue liraglutide, hereby improving glycaemic control and
reducing risk factors of cardiovascular disease
Phase:
Phase 4
Details
Lead Sponsor:
Bo Feldt-Rasmussen
Collaborators:
Novo Nordisk A/S The GCP unit at Copenhagen University Hospital